Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

“These data show how we are strengthening our IMPACT platform to serve as our product engine, creating a range of biologic therapies designed to address diseases more effectively by optimizing ...

Explore key properties for optimizing biologic dry powder formulations: stabilize molecule, ensure device compatibility, maximize therapy effectiveness.

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product ...

Ocugen Inc ( (OCGN) ) has released its Q3 earnings. Here is a breakdown of the information Ocugen Inc presented to its investors. Ocugen, Inc.

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –MELVILLE, N.Y., ...

Researchers at Tel Aviv University and the Sagol Center for Hyperbaric Medicine and Research at the Shamir Medical Center have demonstrated that hyperbaric oxygen therapy (HBOT) improves the condition ...

Good afternoon, and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia, and I will facilitate ...